Education on FDA regulation of Human Cellular Tissue Products (HCTPs).
Source-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- VIVEX BIOLOGICS
- Filing UUID
- 82431e11-4d4b-432b-8b5b-b0b6abdfead2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Literal federal measure citations: H.R. 5768, S. 2561, H.R.6852
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.